**Trader consensus on no hantavirus vaccine approval by the end of 2026 reflects the early-stage pipeline and standard regulatory timelines for a rare disease.** No candidate has completed Phase 3 efficacy trials or advanced to regulatory submission. Preclinical mRNA platforms, including single-dose Andes virus candidates that achieved 100% protection in Syrian hamster models, and a completed Phase 1 DNA vaccine showing neutralizing antibodies in humans remain years from licensure. Recent animal data and a 2026 cruise-ship cluster have heightened visibility, yet development faces challenges including strain diversity, limited large-animal models, and the difficulty of conducting field efficacy studies for sporadic rodent-borne infections. Official sources confirm no licensed products exist for New World hantaviruses in major markets, and even accelerated pathways require substantial safety and efficacy data not yet generated. New Phase 1 starts or model updates could refine sentiment, but current conditions support the market-implied odds.
Eksperimental na AI-generated summary na nire-reference ang Polymarket data. Hindi ito trading advice at wala itong papel sa kung paano nire-resolve ang market na ito. · Na-updateHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
3% tsansa
$138,610 Vol.
$138,610 Vol.
Dec 31, 2026
3% tsansa
$138,610 Vol.
$138,610 Vol.
Dec 31, 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.**Trader consensus on no hantavirus vaccine approval by the end of 2026 reflects the early-stage pipeline and standard regulatory timelines for a rare disease.** No candidate has completed Phase 3 efficacy trials or advanced to regulatory submission. Preclinical mRNA platforms, including single-dose Andes virus candidates that achieved 100% protection in Syrian hamster models, and a completed Phase 1 DNA vaccine showing neutralizing antibodies in humans remain years from licensure. Recent animal data and a 2026 cruise-ship cluster have heightened visibility, yet development faces challenges including strain diversity, limited large-animal models, and the difficulty of conducting field efficacy studies for sporadic rodent-borne infections. Official sources confirm no licensed products exist for New World hantaviruses in major markets, and even accelerated pathways require substantial safety and efficacy data not yet generated. New Phase 1 starts or model updates could refine sentiment, but current conditions support the market-implied odds.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Binuksan ang Market: May 4, 2026, 10:39 AM ET
Volume
$138,610Petsa ng Pagtatapos
Jan 1, 2027Binuksan ang Market
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.**Trader consensus on no hantavirus vaccine approval by the end of 2026 reflects the early-stage pipeline and standard regulatory timelines for a rare disease.** No candidate has completed Phase 3 efficacy trials or advanced to regulatory submission. Preclinical mRNA platforms, including single-dose Andes virus candidates that achieved 100% protection in Syrian hamster models, and a completed Phase 1 DNA vaccine showing neutralizing antibodies in humans remain years from licensure. Recent animal data and a 2026 cruise-ship cluster have heightened visibility, yet development faces challenges including strain diversity, limited large-animal models, and the difficulty of conducting field efficacy studies for sporadic rodent-borne infections. Official sources confirm no licensed products exist for New World hantaviruses in major markets, and even accelerated pathways require substantial safety and efficacy data not yet generated. New Phase 1 starts or model updates could refine sentiment, but current conditions support the market-implied odds.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Volume
$138,610Petsa ng Pagtatapos
Jan 1, 2027Binuksan ang Market
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...**Trader consensus on no hantavirus vaccine approval by the end of 2026 reflects the early-stage pipeline and standard regulatory timelines for a rare disease.** No candidate has completed Phase 3 efficacy trials or advanced to regulatory submission. Preclinical mRNA platforms, including single-dose Andes virus candidates that achieved 100% protection in Syrian hamster models, and a completed Phase 1 DNA vaccine showing neutralizing antibodies in humans remain years from licensure. Recent animal data and a 2026 cruise-ship cluster have heightened visibility, yet development faces challenges including strain diversity, limited large-animal models, and the difficulty of conducting field efficacy studies for sporadic rodent-borne infections. Official sources confirm no licensed products exist for New World hantaviruses in major markets, and even accelerated pathways require substantial safety and efficacy data not yet generated. New Phase 1 starts or model updates could refine sentiment, but current conditions support the market-implied odds.
Eksperimental na AI-generated summary na nire-reference ang Polymarket data. Hindi ito trading advice at wala itong papel sa kung paano nire-resolve ang market na ito. · Na-update
Mag-ingat sa mga external link.
Mag-ingat sa mga external link.
Mga Madalas na Tanong